Agomab Therapeutics NV

424B4 priced

Price $16.00 · 12,500,000 shares · Gross proceeds $200,000,000

CERT inactive

8-A12B effective

EFFECT effective

F-1/A amended

Range $15.00 to $17.00 · 12,500,000 shares · Gross proceeds $212,500,000

F-1 filed

DRS/A amended

DRS/A amended

Agomab Therapeutics NV, a clinical-stage biopharmaceutical company, is conducting an initial public offering (IPO) of American Depositary Shares (ADSs) representing common shares. The company focuses on developing disease-modifying therapies for immunology and inflammatory diseases, with a primary emphasis on fibrotic conditions. Its lead candidate, ontunisertib (AGMB-129), targets the TGF-β pathway for Fibrostenosing Crohn’s Disease. The IPO aims to raise capital for clinical development and commercialization, with ADSs expected to be listed on Nasdaq under the symbol 'AGMB'. The offering is contingent on Nasdaq approval, and the company is an emerging growth company and foreign private issuer under U.S. securities laws.

DRS filed

Agomab Therapeutics NV is a clinical-stage biopharmaceutical company developing novel therapies for immunology and inflammatory diseases, with a focus on fibrotic disorders. Its lead candidate, AGMB-129, targets the TGF and HGF pathways for Fibrostenosing Crohn’s Disease (FSCD), a severe complication with no approved pharmacologic treatments. The company is an emerging growth company and has filed a registration statement for an initial public offering (IPO) of American Depositary Shares (ADSs), with underwriters including J.P. Morgan, Morgan Stanley, and others. The ADSs are expected to be listed on Nasdaq under the symbol 'AGMB'.